Calamos Advisors LLC Makes New $1.09 Million Investment in Harrow, Inc. $HROW

Calamos Advisors LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 22,575 shares of the company’s stock, valued at approximately $1,088,000. Calamos Advisors LLC owned approximately 0.06% of Harrow as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Harrow during the 3rd quarter worth $251,000. Tripletail Wealth Management LLC acquired a new position in Harrow during the third quarter worth about $221,000. Perigon Wealth Management LLC bought a new position in shares of Harrow in the third quarter worth about $416,000. Apollon Wealth Management LLC acquired a new stake in shares of Harrow in the 3rd quarter valued at approximately $226,000. Finally, Brookstone Capital Management boosted its stake in shares of Harrow by 232.5% in the 3rd quarter. Brookstone Capital Management now owns 45,775 shares of the company’s stock valued at $2,205,000 after purchasing an additional 32,009 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Price Performance

HROW stock opened at $49.00 on Friday. The company has a market capitalization of $1.81 billion, a P/E ratio of -489.95 and a beta of 0.02. The company has a fifty day moving average price of $42.53 and a 200-day moving average price of $39.24. The company has a debt-to-equity ratio of 5.21, a quick ratio of 2.52 and a current ratio of 2.72. Harrow, Inc. has a 52-week low of $20.85 and a 52-week high of $51.53.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.11. The business had revenue of $71.64 million during the quarter, compared to the consensus estimate of $73.70 million. Harrow had a positive return on equity of 28.71% and a negative net margin of 1.99%. As a group, equities analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and set a $63.00 price target on shares of Harrow in a report on Wednesday, September 24th. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a report on Friday, September 12th. B. Riley restated a “buy” rating and set a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Finally, HC Wainwright upped their target price on Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.43.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.